Recombinant Antihemophilic Factor Viii
About Recombinant Antihemophilic Factor Viii
Recombinant Antihemophilic Factor Viii belongs to the class of medicines called antihemophilic drugs, primarily used to treat haemophilia A (classical haemophilia) for the prevention and control of hemorrhagic episodes. Recombinant Antihemophilic Factor Viii is also used in the perioperative management of patients with classical haemophilia.
Recombinant Antihemophilic Factor Viii containing Recombinant Anti-hemophilic Factor, a blood clotting protein. It works by increasing plasma levels of factor VIII activity in patients with Hemophilia.
Recombinant Antihemophilic Factor Viii will be administered by a healthcare professional; do not self-administer. This medicine may cause side effects such as headache, nausea, chills, fever, dizziness, fatigue, flushing, and pain at the injection site. These side effects may not occur in everyone using this medication and gradually resolve over time.
Recombinant Antihemophilic Factor Viii should be avoided if allergic to it. Before starting Recombinant Antihemophilic Factor Viii, let your doctor know if you have any medical history of liver/kidney disease, blood pressure problems, or heart problems/failure. Pregnant and breastfeeding women should consult their doctor before using Recombinant Antihemophilic Factor Viii.
Uses of Recombinant Antihemophilic Factor Viii
Medicinal Benefits
Recombinant Antihemophilic Factor Viii is a blood clotting protein that contains a Recombinant Anti-hemophilic Factor. It works by increasing plasma levels of factor VIII activity in patients with Hemophilia and thereby helps clot the bleeding when our body’s clotting factors do not respond. Recombinant Antihemophilic Factor Viii is not recommended for use in patients diagnosed with Von Willebrand’s disease Type I.
Directions for Use
Recombinant Antihemophilic Factor Viii will be administered by a healthcare professional; do not self-administer.
Storage
Side Effects of Recombinant Antihemophilic Factor Viii
- Fever
- Nausea
- Fatigue
- Flushing of the face
- Fast or irregular heart rate
- Low blood pressure
- Redness/pain/swelling at the injection site
- Severe allergic reactions
- Chills
- Headache
- Dizziness
Drug Warnings
Discontinue the medicine and inform your doctor if you develop any severe allergic reactions during the treatment course. Recombinant Antihemophilic Factor Viii is not indicated in treating patients with Von Willebrand’s disease Type I and when there is evidence of an abnormal molecular form of factor VIII antigen. Inform your doctor if you have any history of liver/kidney disease, fluid retention, low blood pressure, heart problems, conditions that cause fluid/mineral imbalance (cystic fibrosis), and heart failure. Please consult your doctor before starting Recombinant Antihemophilic Factor Viii if you are pregnant, planning to conceive or are a breastfeeding mother. Recombinant Antihemophilic Factor Viii is known to cause severe hypersensitivity reactions. Hence, the patient should be monitored carefully for any changes. This medicine is safe for use in children if prescribed by the physician.
Drug Interactions
Drug-Drug Interactions: Recombinant Antihemophilic Factor Viii may interact with antineoplastic drugs (carfilzomib), anti-hemophilic medicine (emicizumab), anti-gout medicine (pegloticase), and other medicines.
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: Recombinant Antihemophilic Factor Viii is contraindicated in Von Willebrand’s disease Type I. Caution should be exercised in patients with liver/kidney disease, heart failure, cardiac conditions, low blood pressure, and hypersensitivity reactions.
Drug-Drug Interactions Checker List:
Safety Advice
Alcohol
consult your doctorIt is unknown whether Recombinant Antihemophilic Factor Viii interacts with alcohol. Please consult your doctor.
Pregnancy
cautionIf you are pregnant or planning pregnancy, inform your doctor before receiving Recombinant Antihemophilic Factor Viii. Your doctor may prescribe this medicine if the benefits outweigh the risks.
Breast Feeding
cautionThere is limited information on how Recombinant Antihemophilic Factor Viii affects breastfeeding. If you are breastfeeding, inform your doctor before receiving Recombinant Antihemophilic Factor Viii.
Driving
cautionRecombinant Antihemophilic Factor Viii will be administered in the hospital setting. Hence, avoid driving.
Liver
cautionPlease let your doctor know if you have any history of liver disease before receiving Recombinant Antihemophilic Factor Viii. Your doctor may adjust the dose if needed based on the clinical condition.
Kidney
cautionPlease let your doctor know if you have any history of kidney disease before receiving Recombinant Antihemophilic Factor Viii. Your doctor may adjust the dose if needed based on the clinical condition.
Children
safe if prescribedRecombinant Antihemophilic Factor Viii is safe for use in children below 12 years of age if prescribed by the physician.
Habit Forming
Diet & Lifestyle Advise
- Maintain a fibre-rich diet and include healthy carbohydrates from fruits, vegetables and whole grains.
- Avoid drinking coffee, tea, cola, energy drinks, or other caffeine sources before bedtime since it can lead to increased urination.
- Avoid activities that cause dehydration, such as excessive physical exercise or spending time in the heat.
- Optimal water intake is recommended to prevent dehydration due to excessive urination.
Special Advise
- Please ensure the serum sodium concentration is normal before starting or resuming the desmopressin injection.
- Regular monitoring of electrolytes is essential to rule out chances of fluid imbalance.
- Your doctor may advise kidney functioning tests to monitor for renal impairment.
- Frequent monitoring of plasma factor VIII activity levels will be suggested during the treatment period to ensure adequate factor VIII levels have been achieved.
Patients Concern
Disease/Condition Glossary
Hemophilia A: Also known as classical haemophilia. It is an inherited bleeding disorder in which the blood does not clot normally. It mainly occurs due to the congenital lack of coagulation factor VIII. Symptoms include unusual bleeding after vaccinations, large or deep bruises, joint pain and swelling, and blood in urine or stool.
FAQs
Recombinant Antihemophilic Factor Viii is used to treat Hemophilia A.
Recombinant Antihemophilic Factor Viii works by increasing plasma levels of factor VIII activity in patients with Hemophilia.
Do not use Recombinant Antihemophilic Factor Viii if you have polyuria that has not been diagnosed. It is advised to use the Recombinant Antihemophilic Factor Viii only when the doctor has suggested it for you, depending on your medical condition.
